BETA: Please send your feedback!
PTC Therapeutics
PTCT:NAS
Biotechnology
$2.57bn
SMALL cap
$43.68
(-1.49%)
0.27%
since start of 2019
-10.76
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Pharmaceuticals: Other
Founded 2002
Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
website
Headquarters
Executives
| Name | Title | Gender |
| Michael Schmertzler, MBA | Chairman | Male |
| Stuart W. Peltz, PhD | Chief Executive Officer & Class I Director | Male |
| Mark Elliott Boulding | Secretary, Chief Legal Officer & Executive VP | Male |
| Allan Steven Jacobson, PhD | Independent Class III Director | Male |
| Martin Rexroad | Senior Vice President-Human Resources | Male |
| Jane Baj | Head-Investor Relations | Female |
| Neil Gregory Almstead, PhD | Executive VP-Research, Operations & Technology | Male |
| Shane William Charles Kovacs, CFA, MBA | CFO & Head-Corporate Development | Male |
| Tuyen Ong, MD, MBA | Chief Medical Officer | null |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Intercept Pharmaceuticals - Competitors and Related Companies
How Intercept Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Intercept Pharmaceuticals
ICPT:NAS
Pharmaceuticals: Other
$1.99bn
SMALL cap
$60.90
(-2.08%)
-0.41%
since start of 2019
-5.82
Loading…